Medical/Pharmaceuticals

Harbour BioMed Announces Upcoming Poster Presentations at the 37th Society for Immunotherapy of Cancer Annual Meeting

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Oct. 13, 2022 /PRNewswire/ -- Harbour BioMed (the "Company", HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunol...

2022-10-13 19:05 2182

Samsung Biologics obtains three global ISO certifications

* Receives accreditation for information security management system, information security in cloud services, and anti-bribery management systems * First global CDMO to be ISO 27001 and ISO 27017 certified * Earns Excellence Award for Integrated Management System from BSI for its performance ...

2022-10-13 19:00 2307

Guiyang's Wudang district shines in pharma sector

GUIYANG, Oct. 12, 2022 /PRNewswire/ -- A news report from chinadaily.com.cn:  Southwest China's Guizhou province – one of the four main regions for traditional Chinese medicine materials production inChina – has abundant medicine resources and a long history in ethnic medicine, and these days, it...

2022-10-13 10:12 1649

United Imaging Ships Global Installations Number 20,000, 20,001 and 20,002 from its Houston Headquarters to New York City

Fresh off the heels of its recent IPO, the company continues its steady U.S. growth. HOUSTON, Oct. 12, 2022 /PRNewswire/ -- United Imaging, a global leader in producing advanced medical imaging and radiotherapy equipment, announced that it is now shipping its 20,000th installation and two additi...

2022-10-12 21:00 2025

Great Bay Bio Announces Official Launch of Site-Specific Integration Platform for Cell Line Development, AlfaCell®

HONG KONG, Oct. 11, 2022 /PRNewswire/ -- Great Bay Bio (hereinafter referred to as "GBB") today announces the official launch of its self-developed AI-enabled site-specific integration platform for cell line development (CLD), AlfaCell®. AlfaCell® platform has pioneered to integrate GBB's proprie...

2022-10-11 20:40 2556

HanAll's Licensed Partner in China Enters Sublicense Agreement with CSPC to Further Accelerate Development of Batoclimab

* Harbour BioMed, HanAll's licensed partner in China, signed a sublicense agreement with CSPC NBP Pharmaceutical for batoclimab, an FcRn compound originally discovered and developed by HanAll Biopharma * Batoclimab is one of the most advanced FcRn inhibitors being developed in Greater China, ...

2022-10-11 19:00 1996

Samsung Biologics unlocks additional capacity for production at its newest Plant 4

* Plant 4 commences GMP operations within just 23 months since groundbreaking, as planned * Partial operations add fresh biomanufacturing capacity of 60,000 liters * Plant 4's total capacity of 240,000 liters to be ready early next year INCHEON,South Korea, Oct. 11, 2022 /PRNewswire/ -- Sams...

2022-10-11 19:00 2245

IASO Biotherapeutics and Cabaletta Bio Announce Exclusive Worldwide License Agreement for Clinically Validated CD19 Binder

PHILADELPHIA and SAN JOSE, Calif. and NANJING and SHANGHAI, China, Oct. 11, 2022 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a clinical-stage biopharmaceutical company engaged in discovering, developing, and manufacturing innovative medicines and Cabaletta Bio, Inc. (Nasdaq: CABA), a clini...

2022-10-11 19:00 2519

Actinogen Medical Limited (ACW) announces large Xanamem® therapeutic effect in early-stage Alzheimer's Disease (AD) patients

Clinical Dementia Rating Scale - Sum of Boxes effect of 0.6 to 0.8 points observed in patients with elevated pTau biomarker with once daily, 10 mg, oral therapy SYDNEY, Oct. 10, 2022 /PRNewswire/ -- Actinogen Medical Limited (ASX: ACW) today announces positive Phase 2a clinical data from its Alz...

2022-10-10 20:00 2440

Hugel resubmits BLA for its botulinum toxin, Botulax to the U.S. FDA

* Hugel received CRL from the U.S. FDA last March and completely supplemented documents and data. * It is expected to obtain the U.S. FDA's approval in the first half of 2023 and aims to become a TOP 3 botulinum toxin brand in the U.S. market. SEOUL, South Korea, Oct. 7, 2022 /PRNewswire/ -- ...

2022-10-08 11:00 3015

Antengene Announces Upcoming Presentations at the 2022 Society for Immunotherapy of Cancer Annual Meeting

* Oral presentation highlights preclinical data of ATG-031, an in-house discovered anti-CD24 monoclonal antibody * Three poster presentations showcase preclinical data of ATG-101, a PD-L1/4-1BB bispecific antibody developed in-house, ATG-018, an ATR inhibitor discovered in-house, and ATG-027,...

2022-10-08 10:43 3049

First patient treated in Clarity's therapeutic prostate cancer trial

Highlights * Clarity Pharmaceuticals recruits and treats its first patient in the therapeutic phase of its SAR-bisPSMA theranostic clinical trial SECuRE (NCT04868604)[1] investigating Targeted Copper Theranostics (TCTs) in patients with metastatic castrate-resistant prostate cancer (mCRPC) ...

2022-10-07 21:06 2536

United Imaging Installs Broward County's First uMI 550 at Holy Cross Health in Fort Lauderdale

Holy Cross procured the uMI 550 to "go digital" and continue to innovate for its community. HOUSTON, Oct. 6, 2022 /PRNewswire/ -- United Imaging, a global manufacturer of medical imaging equipment, announced the installation ofBroward County's first uMI 550 at Holy Cross Health, a member of Trin...

2022-10-07 00:00 1853

HanAll's Second FcRn Inhibitor HL161ANS to be Added to the Development Program of its Licensed Partner

* Immunovant, a HanAll's licensed partner, unveiled its plan to develop a new FcRn inhibitor, HL161ANS (also known as IMVT-1402) * In animal studies, HL161ANS indicated deep IgG reductions similar to batoclimab with no or minimal impact on albumin and LDL cholesterol level * Batoclimab (form...

2022-10-04 19:00 2138

Hayashibara Brings Back "Trehalose Symposium" to Reveal Its Game-changing Versatilities in Human Biochemistry

OKAYAMA, Japan, Oct. 4, 2022 /PRNewswire/ -- Hayashibara Co., Ltd., a member of Nagase Group and headquartered in Okayama City, westernJapan, hosted the 24th Trehalose Symposium, with the support of the Japanese Society of Applied Glycoscience, onSeptember 8, 2022. Photo: https://kyodonewsprwir...

2022-10-04 14:00 1681

Duality announced the appointment of Dr. Yver as Chairman of SAB

PRINCETON, N. J. and SHANGHAI, SUZHOU, China, Oct. 3, 2022 /PRNewswire/ -- Duality Biotherapeutics, Inc. ("Duality" or "the Company") today announced the appointment of Dr.Antoine Yver as Chairman of SAB. Dr. Antoine Yver will provide strategic advice and guidance for the Company's R&D and pipeli...

2022-10-03 22:00 2336

DetectedX to Provide Free Access to Radiology Online Learning Platform to Radiology Across Borders to Enhance Global Charity's Teaching Initiatives

Radiology Across Borders will Promote Access to DetectedX's On-Demand, Web-Based Educational Platform to Clinicians from Developing Nations to Improve Diagnostic Accuracy SYDNEY, Oct. 3, 2022 /PRNewswire/ -- DetectedX announced today that it will provide free access to its Radiology Online Learn...

2022-10-03 20:00 2325

Estrella Biopharma, Inc., a biopharmaceutical company to Become a Publicly Traded Company Via Merger with TradeUP Acquisition Corp.

NEW YORK, Oct. 3, 2022 /PRNewswire/ -- Estrella Biopharma, Inc. ("Estrella"), a preclinical-stage biopharmaceutical company focusing on cancer therapeutics, and TradeUP Acquisition Corp. ("TradeUP") (NASDAQ: UPTD), a publicly traded special purpose acquisition company, today announced that they h...

2022-10-03 19:27 4033

AeroRx Partners with HCmed to Develop a Nebulized LABA/LAMA Combination Solution for the Treatment of Chronic Obstructive Pulmonary Disease

TAIPEI, Oct. 2, 2022 /PRNewswire/ -- AeroRx Therapeutics, LLC. (AeroRx) and HCmed Innovations Co., Ltd. (HCmed) have initiated a collaboration, introducing a LABA/LAMA combination solution for delivery with a breath-actuated nebulizer. This collaboration sets forth the framework by which both com...

2022-10-03 09:00 2070

Qilian International Holding Group Limited Reports Financial Results for the First Six Months of Fiscal Year 2022

JIUQUAN, China, Sept. 30, 2022 /PRNewswire/ -- Qilian International Holding Group Limited (Nasdaq: QLI) (the "Company"), aChina-based pharmaceutical and chemical products manufacturer, today announced its unaudited financial results for the first six months of fiscal year 2022 endedMarch 31, 2022...

2022-10-01 04:30 5673
1 ... 203204205206207208209 ... 261

Week's Top Stories